Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cellino Biotech Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, meaning that every active matter is being reviewed by a different individual. This lack of examiner overlap across the 3 pending office actions suggests that the company must tailor its advocacy to separate sets of examiner preferences and backgrounds.
The portfolio's active matters are situated within 2 distinct art units. While there are distinct examiners involved, the fact that they operate within 2 distinct art units indicates some level of institutional consistency in the technology being examined. NOBLE, MARCIA STEPHENS is designated as the busiest examiner, though she is responsible for 1 busiest examiner pending action. This reflects the distribution of the workload, as no individual examiner holds more than 1 of the pending actions.
For the practitioner, this data highlights a decentralized prosecution environment. With the 3 pending office actions spread across the distinct examiners, there is no single point of contact to influence the majority of the portfolio. Strategy must be developed independently for each action, even as they remain clustered within the 2 distinct art units in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| PEARSON, AMANDA HYEONWOO | 1 | 67.6% | +32.4% |
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18234342 | SYSTEMS AND METHODS FOR CELL MANUFACTURING | NOBLE, MARCIA STEPHENS | — |
| 17267383 | SYSTEM FOR IMAGE-DRIVEN CELL MANUFACTURING | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18234342 | SYSTEMS AND METHODS FOR CELL MANUFACTURING | NOBLE, MARCIA STEPHENS | — |
| 18308448 | PLATFORMS AND SYSTEMS FOR AUTOMATED CELL CULTURE | PEARSON, AMANDA HYEONWOO | — |
| 17267383 | SYSTEM FOR IMAGE-DRIVEN CELL MANUFACTURING | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18234342 | SYSTEMS AND METHODS FOR CELL MANUFACTURING | NOBLE, MARCIA STEPHENS | 1632 | §102§103§112Other | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18308448 | PLATFORMS AND SYSTEMS FOR AUTOMATED CELL CULTURE | PEARSON, AMANDA HYEONWOO | — | §103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 17267383 | SYSTEM FOR IMAGE-DRIVEN CELL MANUFACTURING | LEITH, NANCY J | 1600 | §103§112Other | Non-Final OA | — | Pending | Feb 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial